| Name | Title | Contact Details |
|---|
Drummond Advisors provides global consulting services to companies focusing on accounting, tax, legal and business development. Founded in Boston, the consulting firm expanded its presence to the cities of Miami, Orlando, São Paulo and Belo Horizonte as a result of the growth of its customer base with the goal of providing personalized service. The company reunites a multidisciplinary team of professionals with certification, training and experience in Brazilian and North American territory.
Placing small E&S risks shouldnt be hard. Pathpoint was built to make it faster and easier for retail agents to get great E&S coverage options. Quote and bind coverage for your small business clients online with one streamlined submission. Receive multiple bindable quotes for your clients in minutes, not days.
Nobu, the world-renowned Japanese restaurant recognized for pioneering a new-style Japanese cuisine, started as a business partnership in 1994 between Chef Nobu Matsuhisa and his partners, Academy Award-winning actor Robert De Niro, producer Meir Teper, and restaurateur Drew Nieporent. Originating in New York as the flagship restaurant, the Nobu brand is now an empire that spans five continents with over 40 restaurants and growing. Following the success of the restaurants, Nobu Hospitality opened the first Nobu Hotel in 2013 in Las Vegas and today has 13 hotels open with several more in development.
Your Single Source for all IT & Cybersecurity Solutions NuView Advisors is a group of vCIO/vCTO/vCISO and IT professionals with decades working with organizations of all sizes to standardize IT and Cybersecurity service delivery to the highest standards. Working with NuView is a force multiplier for IT and Cybersecurity departments to focus on higher value strategic activities, streamlining services across existing organizations and helping startups quickly build their IT services for security and scale.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.